Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $314,400.00 in Stock

Posted by Geri Gentry on May 21st, 2026

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $20.96, for a total transaction of $314,400.00. Following the completion of the sale, the insider directly owned 334,786 shares in the company, valued at approximately $7,017,114.56. This represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Brian Daniel Webster also recently made the following trade(s):

On Wednesday, April 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.04, for a total transaction of $300,600.00.
On Tuesday, March 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.27, for a total transaction of $304,050.00.
On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.60, for a total transaction of $384,000.00.

Kestra Medical Technologies Trading Up 4.8%

NASDAQ:KMTS opened at $20.76 on Thursday. The firm’s fifty day moving average is $20.53 and its 200-day moving average is $23.76. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. Kestra Medical Technologies, Ltd. has a 52 week low of $13.25 and a 52 week high of $30.00. The firm has a market cap of $1.21 billion, a P/E ratio of -5.24 and a beta of 0.82.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm had revenue of $24.55 million during the quarter. The business’s revenue for the quarter was up 62.7% compared to the same quarter last year. Equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC bought a new position in Kestra Medical Technologies during the fourth quarter worth $31,000. Russell Investments Group Ltd. boosted its stake in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after acquiring an additional 474 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Kestra Medical Technologies during the third quarter worth $48,000. Daiwa Securities Group Inc. bought a new position in Kestra Medical Technologies during the fourth quarter worth $72,000. Finally, BNP Paribas Financial Markets boosted its stake in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. BTIG Research reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Monday, March 23rd. Finally, The Goldman Sachs Group cut their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $27.40.

Get Our Latest Report on Kestra Medical Technologies

About Kestra Medical Technologies

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.